Camurus AB (publ) (STO:CAMX)

Market Cap	30.03B -13.0%
Revenue (ttm)	2.27B +21.3%
Net Income	735.57M +71.7%
EPS	12.26 +70.3%
Shares Out	59.69M
PE Ratio	41.03
Forward PE	31.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	218,894
Average Volume	194,733
Open	505.50
Previous Close	506.00
Day's Range	494.00 - 508.00
52-Week Range	483.80 - 754.50
Beta	0.50
RSI	31.28
Earnings Date	Feb 12, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 285
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CAMX

Financial Performance

In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.